MMV is grateful for the support of its institutional donors.

Why is defeating malaria important?

A child dies every minute of every day from malaria.

247 million people suffer, and over 600,000 people lost their lives in 2021.1

It is widespread and endemic in 84 countries.

It is a cause and consequence of poverty.

It exacerbates gender inequality for women and girls.

Eliminating malaria is essential if we are to achieve the SDGs.

2. WHO World Malaria Report 2022

Developing antimalarials to save lives

MMV reduces the burden of malaria in disease-endemic countries by discovering, developing and delivering new effective and affordable antimalarial drugs.

Curing / preventing / eliminating malaria

13.6 million lives saved
Drug innovation for underserved populations

Malaria disproportionately impacts underserved people, often those living in poor rural areas, and especially children and women.

Because malaria is a disease of poverty, there is little commercial incentive for private companies to innovate and address the challenges of distribution of antimalarials in difficult settings.

**MMV aims to fill this drug innovation gap**

MMV leverages the expertise and resources of a network of partners (donors, researchers, as well as pharmaceutical and distribution partners) to discover, develop and deliver new medicines.

Once developed, MMV works with additional partners including country health ministries, national and international organizations, and distribution partners to be sure that the new medicines are effectively delivered to those who need them most. This includes children, babies and their families, pregnant women and communities most affected by malaria.

---

**MMV’s malaria highlights**

- First child-friendly drug launched in 2009, now the most widely used.
- 49 million children received seasonal prevention in 2022.
- First African manufactured drug for prevention of malaria in pregnant women.
- First WHO policy drug recommendation for first-trimester pregnant women.
The Sustainable Development Goals are a call to action to end poverty and inequality, protect the planet, and ensure that all people enjoy health, justice and prosperity. MMV’s work to reduce the burden of malaria contributes to eight of these goals.

1. MMV develops and facilitates access to affordable and effective therapies, key to mitigating the impact of malaria on poor populations.
2. MMV and partners have assembled the largest-ever portfolio of antimalarials, supporting target 3.3 (to end malaria and other diseases).
3. Malaria disproportionately affects women as patients and caregivers. MMV prioritizes new medicines specifically for use by pregnant women and girls.
4. Partnership is at the core of MMV. We bring together academia, pharma, research institutes, philanthropic organizations and funders to make malaria drug research happen.
5. MMV works to defeat malaria, a disease that is expected to cause 60,000 additional deaths per year by 2050 due to climate change, according to the WHO.
6. MMV is committed to facilitating equitable access to antimalarials for under-served populations, across all gender, age and socio-economic categories.
7. MMV works with drug research and manufacturing partners in endemic countries to help strengthen local capabilities and achieve global quality standards.
8. MMV advances the availability of antimalarials for workers and their families, contributing to decreased absenteeism at work and school, thus fostering a brighter future.
9. MMV supports building antimalarial expertise.
10. MMV develops and facilitates access to affordable and effective therapies, key to mitigating the impact of malaria on poor populations.
11. MMV and partners have assembled the largest-ever portfolio of antimalarials, supporting target 3.3 (to end malaria and other diseases).
12. Partnership is at the core of MMV. We bring together academia, pharma, research institutes, philanthropic organizations and funders to make malaria drug research happen.
13. MMV works to defeat malaria, a disease that is expected to cause 60,000 additional deaths per year by 2050 due to climate change, according to the WHO.
14. MMV is committed to facilitating equitable access to antimalarials for under-served populations, across all gender, age and socio-economic categories.
15. MMV works with drug research and manufacturing partners in endemic countries to help strengthen local capabilities and achieve global quality standards.
Challenges to eliminating malaria

Some concerning trends\(^2\) require continued effort and funding:

- Progress in reducing malaria cases and deaths has stalled over recent years.
- Increasing antimalarial drug resistance.
- Climate change and its impact on the disease.
- Fragile local health systems.
- Mosquito species spreading to cities.

Which is why MMV continues to work to secure a robust pipeline of anti-malarial drugs to serve the populations most at need.

Defeating malaria together

MMV is grateful for the support of its institutional donors

© September 2023 Medicines for Malaria Venture - All rights reserved
Photos credits: Emmanuel Museruka - Design: Comstone - Geneva
© September 2023 Medicines for Malaria Venture - All rights reserved

Medicines for Malaria Venture (MMV)
T +41 22 555 03 00 | www.mmv.org | communications@mmv.org

Subscribe to MMV’s monthly newsletter to receive the latest news about our work to defeat malaria.
https://www.mmv.org/subscribe